Literature DB >> 10415336

PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation.

A K Ghosh1, I Grigorieva, R Steele, R G Hoover, R B Ray.   

Abstract

A novel tumor suppressor gene, PTEN, has recently been identified at chromosome 10q23, which is inactivated in a number of different tumor types including breast cancer. An investigation of the functional role suggested that PTEN transcriptionally represses both exogenous and endogenous c-myc expressions in human breast carcinoma cells. PTEN, when ectopically expressed in human breast carcinoma cells, exhibited an inhibition of phosphorylation of both activating residues of protein kinase B (PKB)/AKT at Ser-473 and Thr-308 without any significant alteration of AKT expression. Furthermore, introduction of PTEN into human breast carcinoma cells induced apoptotic cell death and inhibited cell growth and tumor formation in nude mice. Taken together, our data suggest that PTEN acts as a transcriptional repressor, inhibits the AKT-mediated cell survival signaling pathway, and negatively regulates human breast carcinoma cell growth. These results further emphasize the potential of PTEN as a gene therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415336     DOI: 10.1016/s0378-1119(99)00206-1

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  14 in total

Review 1.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

2.  miR-29b regulates migration of human breast cancer cells.

Authors:  Chen Wang; Zhen Bian; Da Wei; Jian-guo Zhang
Journal:  Mol Cell Biochem       Date:  2011-02-26       Impact factor: 3.396

3.  A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.

Authors:  Xiaoping Huang; Ying Zhang; Yaqiong Tang; Napoleon Butler; Jungeun Kim; Fadila Guessous; David Schiff; James Mandell; Roger Abounader
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

4.  The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.

Authors:  Bozena Konopka; Aneta Janiec-Jankowska; Zygmunt Paszko; Marian Goluda
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-09       Impact factor: 4.553

5.  Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer.

Authors:  Ye-Jiang Zhou; Yu-Xia Xiong; Xiao-Ting Wu; De Shi; Wei Fan; Tong Zhou; Yue-Chun Li; Xiong Huang
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

6.  Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression.

Authors:  Melanie J McConnell; Nathalie Chevallier; Windy Berkofsky-Fessler; Jena M Giltnane; Rupal B Malani; Louis M Staudt; Jonathan D Licht
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

7.  Targeted treatment of differentiated and medullary thyroid cancer.

Authors:  Shannon R Bales; Inder J Chopra
Journal:  J Thyroid Res       Date:  2011-08-02

8.  Inhibition of intrahepatic gamma interferon production by hepatitis C virus nonstructural protein 5A in transgenic mice.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

9.  5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.

Authors:  Francesca Zammarchi; George Boutsalis; Luca Cartegni
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

10.  Expression of the Androgen Receptor, pAkt, and pPTEN in Breast Cancer and Their Potential in Prognostication.

Authors:  Aisha Sultana; Romana Idress; Zulfiqar Ali Naqvi; Iqbal Azam; Shaista Khan; Anwar Ali Siddiqui; El-Nasir Lalani
Journal:  Transl Oncol       Date:  2014-05-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.